Hongyue Dai is an accomplished scientific leader and multifaceted data analyst with over two decades of experience in oncology, immuno-oncology and neural-immune interactions, and is an expert in building and leading bioinformatics teams and capabilities to support drug discovery and development pipelines.

Most recently, Hongyue served as SVP and VP of Bioinformatics and Digital Biology at Cygnal Therapeutics. There, he built a strong Bioinformatics team to support Omics (including single cell RNAseq), image analysis (ML based) pipelines and identified predictive biomarkers and patient populations for internal programs. Prior to his role at Cygnal, Hongyue was a Chief Scientific and Bioinformatics Officer at M2Gen, where he developed and executed molecular strategy for the ORIEN Avatar program (sequenced – 11000 cancer patients by 2019).  Additionally, Hongyue was an Executive Director, Informatics Analyst at Merck, where he led a global team focused on applying genomic and genetic technologies to impact Merck’s pipeline.  Prior to that, Hongyue had a distinguished academic career in high-energy astrophysics, having made a significant contribution to the discovery of the highest energy cosmic ray ever observed, the Oh-My-God particle.

Hongyue received his B.S. in Nuclear Physics from Peking University and his Ph.D. from the Institute of High Energy Physics, Chinese Academy of Science in Beijing, China.